Avance Clinical Accelerates Time to Pivotal Milestones for More Than 700 Emerging Biotechs

Those common hurdles which stall early-stage biotechs are largely due to strategic or operational misalignment. Most often, biotechs experience this in:

• Delayed toxicology data, which can postpone regulatory submission
• Funding gaps, which slow the start of a study or progression to the next phase
• Internal hiring delays, which can leave a client under resourced during critical phases
• Lack of strategic planning, which allows teams to anticipate potential bottlenecks before they occur

Avance Clinical addresses these challenges proactively by assessing early data and preparing regulatory submissions up front. This approach ensures clients can anticipate roadblocks, reduce delays, protect capital from the beginning, and overall provide greater confidence to reach their next inflection point.

“These achievements highlight the strategic value of integrating operational excellence with expert regulatory guidance to de-risk early-stage development,” said Ben Edwards, Chief Operating Officer, at Avance Clinical. “This direction allows us to be the accelerator for our clients to ensure a sustained competitive advantage and progression through later stage development.”